Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19202628 | 0.92 | BTK (0.55) | BTKHTTACACBHPGDSGPR119 | |
| SCHEMBL19203181 | 0.86 | BTK (0.70) | BTKHTTHPGDS | |
| SCHEMBL19202625 | 0.85 | BTK (0.77) | BTK | |
| SCHEMBL19203192 | 0.82 | BTK (0.55) | BTKHTTACACBGPR119 | |
| SCHEMBL19202632 | 0.81 | ACACB (0.42) | BTKACACBGPR119PKM | |
| SCHEMBL19203196 | 0.79 | BTK (0.74) | BTKACACBHPGDSGPR119 | |
| SCHEMBL19202666 | 0.77 | BTK (0.54) | BTKHTTACACBMAPTHPGDS | |
| SCHEMBL16597716 | 0.74 | EGFR (0.50) | BTKHTTMAPTGPR119TP53 | |
| SCHEMBL9409412 | 0.74 | PDE4B (0.59) | MAPTHPGDSGPR119TP53THRB | |
| SCHEMBL20572741 | 0.72 | BTK (0.61) | BTKACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3409672-B1 | PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2021-12-08 | — | — | EP | disclosed |
| EP-3409672-B1 | PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2021-12-08 | — | — | EP | disclosed |
| US-10336755-B2 | Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-07-02 | — | — | US | disclosed |
| US-10336755-B2 | Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-07-02 | — | — | US | disclosed |
| US-20190016721-A1 | FUSED PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND USE THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| US-20190016721-A1 | FUSED PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND USE THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| EP-3409672-A1 | PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2018-12-05 | — | — | EP | disclosed |
| WO-2017128917-A1 | PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | 北京诺诚健华医药科技有限公司 | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336755-B2 | Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases | BTK, SYK, JAK1 | BTK 1/4885HTT 3996/4885ACACB 3969/4885 |
| US-20190016721-A1 | FUSED PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND USE THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | BTK, SYK, JAK1 | BTK 1/4885HTT 3996/4885ACACB 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.